Saturday, July 11, 2026

pharma · Diabetes Mellitus · Hemophilia A

Takeda

Takeda is a pharma organization headquartered in Cambridge, USA. Primary therapeutic focus areas include Diabetes Mellitus, Hemophilia A, Crohn's Disease, Hypertension, Type 2 Diabetes Mellitus. NovaPharmaNews links 1179

Cambridge, USA HQ
1993 Founded
1,617 Employees
NMPA registrant Type
Company details
Clinical program

Stem cells

Phase 2 · gene therapy · Rheumatoid Arthritis Aggravated

Stem cells for Rheumatoid Arthritis Aggravated is a Phase 2 program (gene_therapy) at Takeda with 1 ClinicalTrials.gov record(s).

← All Takeda projects Phase 2 gene therapy completed

Internal code Cx611-0101

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Takeda
Phase
Phase 2
Modality
gene_therapy
Indication
Rheumatoid Arthritis Aggravated
Status
completed
Trials
1